Atlas Trials

Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

Clinical trial NCT04817540 · RECRUITING

Trial details

NCT number
NCT04817540
Sponsor
Gangnam Severance Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
Start date
2021-09-01
Primary completion
2024-03-30
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.